Latest results mixed for Biogen's aducanumab

Biogen Inc. (NASDAQ:BIIB) said a 6 mg/kg dose of aducanumab ( BIIB037) significantly reduced beta amyloid levels, but did not significantly slow cognitive decline, in the Phase Ib PRIME trial to treat prodromal or mild Alzheimer's disease (AD). Data were presented at the Alzheimer's Association International Conference in Washington, D.C.

In March, Biogen reported that 3 mg/kg and 10 mg/kg doses of the human recombinant anti-beta amyloid mAb significantly slowed cognitive decline as measured by the Mini-Mental State Examination (MMSE), while the 10 mg/kg dose also significantly reduced cognitive decline as measured by the Clinical Dementia Rating sum of boxes (CDR-SB). The cognitive endpoints were exploratory (see BioCentury Extra, March 20). ...